Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

935.58 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%

Today 17:25 EDT

As of April 3, 2026, the financial landscape is witnessing a historic disconnect between gritty macroeconomic headlines and exuberant corporate fundamentals. Despite a backdrop of stubborn...

Via MarketMinute

Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗

Today 17:22 EDT

The drugmaker hasn't said its last word yet, as the weight-loss drug battle continues to heat up.

Via The Motley Fool

Where Will Viking Therapeutics Stock Be in 10 Years? ↗

Today 15:46 EDT

There is a wide range of possibilities.

Via The Motley Fool

Stock Of The Day: Where Will Eli Lilly Turn? ↗

April 01, 2026

Eli Lilly (LLY) shares rallied after finding support at a formed resistance level. They may hit resistance at a former support level.

Via Benzinga

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

Today 14:23 EDT

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...

Via MarketMinute

Topics Intellectual Property

Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy ↗

Today 10:35 EDT

Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuticals; Meanwhile, IO Biotech goes bankrupt.

Via Benzinga

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

Today 10:03 EDT

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Via MarketMinute

Topics Economy Government Lawsuit

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

Today 9:51 EDT

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

2 No-Brainer Vanguard ETFs to Buy During the Stock Market Sell-Off ↗

Today 7:13 EDT

Throughout history, investors who bought during stock market declines while maintaining a long-term outlook yielded strong returns.

Via The Motley Fool

Topics ETFs Economy

Dow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh" ↗

April 02, 2026

Markets opened lower on Iran fears and a Tesla stumble, but bounced back. Here's what investors need to know about Thursday's volatile session.

Via The Motley Fool

Topics Government Stocks World Trade

Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring

April 02, 2026

Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require...

Via MarketMinute

Topics Economy

Stock Market Rebounds Even As Oil Prices Skyrocket On Trump's Iran War Comments; Tesla, SpaceX, Eli Lilly In Focus: Weekly Review ↗

April 02, 2026

Tesla deliveries disappointed while Elon Musk's SpaceX filed for an IPO.

Via Investor's Business Daily

Topics Government

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience ↗

April 02, 2026

In a powerful demonstration of financial strength and strategic foresight, Eli Lilly and Company (NYSE: LLY) recently committed over $10 billion to two major initiatives in just a matter of days. While...

Via MarketBeat

Topics Artificial Intelligence

How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss Launch ↗

April 02, 2026

Novo Nordisk said Thursday a new study suggests patients prefer its oral Wegovy over Eli Lilly's new GLP-1 pill, Foundayo.

Via Investor's Business Daily

The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)

April 02, 2026

April 2, 2026 Introduction The Cigna Group (NYSE: CI) stands today at a pivotal crossroads, having undergone one of the most significant strategic transformations in the modern healthcare era. Long...

Via Finterra

Topics Artificial Intelligence Economy Lawsuit

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh ↗

April 02, 2026

Eli Lilly & Co shares are down Thursday despite FDA approval of its oral weight-loss drug Foundayo, as geopolitical tensions weigh on markets.

Via Benzinga

3 Monster Dividend Stocks to Hold for the Next 10 Years ↗

April 02, 2026

These are great and steady income providers for your portfolio.

Via The Motley Fool

Prediction: This Will Be Eli Lilly's Next Billion-Dollar Growth Driver. (Hint: It's Not Weight Loss Drugs.) ↗

April 02, 2026

Moves Lilly has recently made should support a new potential source of growth.

Via The Motley Fool

Topics Artificial Intelligence

Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today ↗

April 01, 2026

GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.

Via Benzinga

Why Eli Lilly Stock Trounced the Market Today ↗

April 01, 2026

Its first weight-loss pill was just approved by the FDA.

Via The Motley Fool

Stock Market Today, April 1: Markets Rally and Oil Prices Fall for Second Day Running ↗

April 01, 2026

Today, April 1, 2026, hopes that the Iran war may soon end drove markets upwards as tumbling oil prices reshaped the day’s winners.

Via The Motley Fool

Topics Economy Stocks

Eli Lilly’s $47.8 Billion Masterstroke: The Contessa Acquisition and the New Era of Pharmaceutical Dominance

April 01, 2026

INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire...

Via MarketMinute

Topics Artificial Intelligence Economy

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

April 01, 2026

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

Via Barchart.com

Could This New Approval Be a Turning Point For Novo Nordisk? ↗

April 01, 2026

The pharmaceutical giant still has plenty of work to do to recover from recent woes.

Via The Motley Fool

Why Is Eli Lilly Stock Gaining Today? ↗

April 01, 2026

Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.

Via Benzinga

Eli Lilly (LLY) Stock Trades Up, Here Is Why

April 01, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.7% in the afternoon session after the FDA approved Foundayo (orforglipro...

Via StockStory

Eli Lilly Jumps After Winning FDA Approval For Obesity Pill ↗

April 01, 2026

Eli Lilly stock jumped midday Wednesday after the FDA approved its weight-loss pill, now called Foundayo.

Via Investor's Business Daily

Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium ↗

April 01, 2026

Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.

Via Benzinga

1 Reason This $900 Stock Could Announce a Split in 2026 ↗

April 01, 2026

This pharmaceutical giant appears well positioned for a potential stock split in 2026.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

Headline News about Eli Lilly

Starting at $3.75/week.

Subscribe Today